SDG9
Industry、Innovation and Infrastructure

Develop quality, reliable, sustainable and resilient infrastructure, adopt clean and environmentally sound technologies and industrial processes, and raise industry’s share of employment and gross domestic product.

NYCU Develops Brain Degeneration Prediction Technology for More Objective Disease Diagnosis

Psychiatric diagnosis has long relied on clinical interviews and patient history, often lacking objective and quantifiable evaluation standards. To tackle this challenge, National Yang Ming Chiao Tung University (NYCU) and Taipei Veterans General Hospital (TVGH) have made groundbreaking advancements in brain imaging and artificial intelligence. Since 2019, Professor Chih-Chieh Yang—Chair

SDGs:
3
9
More

NYCU Breakthrough in Neuromorphic Computing Makes AI Smarter and More Energy-Efficient

Artificial Intelligence (AI) is reshaping our world at an unprecedented pace, driving innovations from autonomous vehicles to medical diagnostics. However, as the demand for AI applications soars, the energy consumption associated with traditional AI computation has become a pressing concern. A research team from the International College of Semiconductor Technology

SDGs:
3
9
More

NYCU and Partners Win “2024 Presidential Hackathon” Excellence Award for Revolutionizing Elderly Healthcare in Taiwan

NYCU and Partners Win “2024 Presidential Hackathon” Excellence Award for Revolutionizing Elderly Healthcare in Taiwan National Yang Ming Chiao Tung University (NYCU) and its partners were honored with the Domestic Track Award at the 2024 Presidential Hackathon awards ceremony held at the Presidential Office on December 22nd. Spearheaded by the Veterans Affairs

SDGs:
3
9
17
More

NYCU Partners with Elixiron Immunotherapeutics to Revolutionize Neuroimmune Therapy Using AI-Powered Drug Development

In a groundbreaking effort to nurture Taiwan’s next generation of biotech talent, National Yang Ming Chiao Tung University (NYCU) has signed a five-year industry-academia collaboration agreement with alumni-founded Elixiron Immunotherapeutics. This partnership will leverage artificial intelligence (AI) to advance drug development, focusing on the clinical trials and commercialization of Enrupatinib,

SDGs:
3
9
17
More